報價延遲最少15分鐘:2024/11/10 13:02 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
15 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.09/-3.76
|
|
企業價值
933.63M
|
| 資產負債 |
|
每股賬面淨值
6.46
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.58M
|
|
每股收益
0.08
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/10 13:02 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis. |